Sign In
Buy SENS
$6.36
-0.380 (-5.64%)
At Close: Jun 22, 2026
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
02:11pm, Thursday, 11'th Jun 2026
SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
03:22pm, Saturday, 06'th Jun 2026
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
08:00am, Monday, 01'st Jun 2026
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
09:07pm, Friday, 08'th May 2026
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring s
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
01:21pm, Friday, 08'th May 2026
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q1 Loss, Beats Revenue Estimates
07:01pm, Thursday, 07'th May 2026
Senseonics Holdings (SENS) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.4 per share a year ago.
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 07'th May 2026
Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, includ
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implanta
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
08:00am, Monday, 04'th May 2026
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring p
Senseonics Shares Sink Friday: What's Driving The Move?
10:06am, Friday, 01'st May 2026
Shares of Senseonics Holdings Inc (NASDAQ:SENS) are trading sharply lower Friday morning following the late-Thursday announcement of the pricing for an $80 million underwritten public offering. Here's
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, im
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
09:50pm, Thursday, 30'th Apr 2026
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,
Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Thursday, 30'th Apr 2026
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,
SENS Launches Eversense 365, World's Only One-Year CGM in Europe
01:30pm, Monday, 27'th Apr 2026
Senseonics launches Eversense 365 in Europe, debuting the first year-long CGM system as it expands into key markets and targets millions of new patients.
